Eisai Incorporated, the United States pharmaceutical subsidiary of Eisai Co Ltd, has named Dr Harald Hampel as its new vice president, Global Medical Affairs, it was reported yesterday.

Dr Hampel will be responsible for creating and managing the company's global AD/dementia medical strategies. He will also oversee investigator-initiated trials, Phase IIIb/IV projects, and the company's continued medical education and medical information programs.

Dr Hampel has 25 years clinical trial experience in Alzheimer's disease and related neurodegenerative diseases and has published more than 600 scientific publications and has won multiple awards for his research. His extensive areas of study have pioneered the field of precision medicine for Alzheimer's disease using systems theory and innovative data science. The founding director of the Alzheimer Memorial Center at the University of Munich in 1997, Dr Hampel most recently served as full professor and excellence chair, scientific director at the Institute for Memory and Alzheimer's Disease, European Center of Excellence in Neurodegenerative Disease at Sorbonne University in Paris, France.